Last week, the stock exchanges experienced a significant wave of selling recommendations from analysts and experts, which unsettled many investors. These experts advise selling certain stocks and instead reallocating to safer investments. These recommendations have direct effects on the investment strategies of private investors.
Stocks Under the Selling Hammer
Among the stocks currently on the experts’ sell lists are:
- Roche: The US bank JPMorgan has maintained Roche at a target price of 220 francs, rating it as ‘Underweight’ and thus recommending a sale.
- GSK (GlaxoSmithKline): Also stamped by JPMorgan with ‘Negative Catalyst Watch’, indicating a negative development.
- GEA Group: Despite a slight upward adjustment in the target price from 45 to 49 euros, JPMorgan remains at the ‘Underweight’ classification.
- Danone: The analysis firm Jefferies continues to classify Danone as ‘Underperform’ with a target price of 61 euros.
What Does This Mean for Private Investors?
For private investors, this specifically means:
- Reviewing their own portfolio regarding these recommended stocks.
- Potentially disposing of riskier positions to minimize risk.
- Increasing the weighting of safer asset classes such as utility stocks or other defensive values.
Although the recent market developments also show positive sides, such as new all-time highs in US markets, the warning signs from these selling recommendations should be taken seriously to avoid losses and to make the portfolio resilient in crises.
In summary, it is clear: The current phase is characterized by increased caution among many experts. Private investors should utilize these signals to critically question and adjust their investment strategy if necessary.